start portlet menu bar end portlet menu bar

Evaluation of different commercially available ELISA's for serological analysis of Aujeszky’s disease in serum samples from wild boars

Strona główna Wiedza Evaluation of different commercially available ELISA's for serological analysis of Aujeszky’s disease in serum samples from wild boars

Evaluation of different commercially available ELISA's for serological analysis of Aujeszky’s disease in serum samples from wild boars

The aim of this study is to evaluate the use of CIVTEST® SUIS ADV, CIVTEST® SUIS ADVgE, CIVTEST® SUIS ADVgB and two other commercially available competition ELISA's to detect antibodies against Aujeszky’s disease virus (ADV) in serum samples from wild boars corresponding to different epidemiological situations.

Pobierz ten artykuł

1,52 MB

O tym artykule

Opublikowano w

WAVLD Meeting (World Association of Veterinary Laboratory Diagnosticians), 2015

Autorzy

Badosa, M.; Martos, A.; Rebordosa, X.; Ruiz, J.F.; González, D.; Porquet, L.

Streszczenie

The results in groups 3 and 4 are those expected according to their epidemiological situation. The percentage of positive animals in group 1 is 64% in all ELISAs. In group 2 this percentage ranges between 35% and 47%, according to the ELISA used.

Powiązane usługi

HIPRASoft

Powiązane produkty

AUSKIPRA® GN

AUSKIPRA® BK

CIVTEST® SUIS ADVgE

CIVTEST® SUIS ADVgB

CIVTEST® SUIS ADV

Powiązane publikacje

Survey of pseudorabies sero-prevalence in 11 provinces of China Retrospective study on the prevalence of Aujeszky's disease in major pig producing provinces in the Philippines (2006-2010) Pseudorabies (Aujeszky’s virus disease) vaccination protocols in China

Udostępnij na

start portlet menu bar

Evaluation of different commercially available ELISA's for serological analysis of Aujeszky’s disease in serum samples from wild boars

Display portlet menu
end portlet menu bar

Patrz także

Publikacje

Intradermal application of vaccines in pigs (Poster)

04-10-2018
Streszczenia choroby

Edema disease

03-11-2017
Aktualności

HIPRA takes a step forward in Taiwan with the launch of UNISTRAIN® PRRS vaccine

11-10-2018